The shift in the ET-receptor balance was indirectly supported by the experimental and clinical studies which showed that selective ETA blockade is usually more advantageous in CKD, and that concomitant ETB receptor blockade might even mitigate the renoprotective effects of ETA antagonists [8,11]. Here, EDNRA is linked to chronic kidney disease.